The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid diverging corporate responses to supply chain hurdles and sector demand, RADCOM Ltd. announced preliminary Q2 results and lowered its full-year 2026 guidance. The company attributed the revision to customer deployment delays caused by rising component costs and supply constraints, adjusting its annual revenue target to a range of $57 million to $63 million. Management emphasized that these dynamics are related to timing issues rather than a fundamental shift in market demand.
In contrast, Vericel Corporation demonstrated robust growth driven by strong demand in sports medicine and burn care markets, raising its full-year 2026 revenue guidance to between $330 million and $340 million. Per market data, VCEL shares closed at $46.71 on July 28, 2026, bolstered by the authorization of a significant $200 million share repurchase program, signaling strong management confidence in the company's financial trajectory relative to its peers.
Investors are closely monitoring RDCM, which stood at $13.08 at the close of July 28, 2026, ahead of its formal earnings release scheduled for August 12, 2026. With no major upcoming sector-specific catalysts in the immediate calendar, market attention remains on supply chain recovery, particularly following recent U.S. Manufacturing PMI data which printed at 53.8.